Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals, Inc.

Corvus is a unique environment for exceptional individuals who want to learn, contribute to an exceptional team, and make a difference in the lives of people with cancer. At Corvus, we take pride in our collaborative, community-based culture. We understand that the most successful teams are those that learn from each other and co-create in an environment that nurtures open, transparent communication.

EcoR1 Capital

Richard A Miller

OrbiMed

Novo Ventures

BlackRock

Rock Springs Capital

Adams Street Partners

Fidelity Management and Research Company

Corvus Pharmaceuticals

Yesterday, we announced our third quarter financial results and provided a business update. We’re pleased to share that the Phase 3 clinical trial protocol for soquelitinib has been finalized and submitted to the FDA, with new Phase 1 data from the T cell lymphoma trial to be presented at the 65th annual American Society of Hematology (#ASH23). 
 
To learn more, read our release: https://lnkd.in/gu3bxRtG

Don't miss our #ASH2023 poster presentation, which will include new interim soquelitinib data from our Phase 1/1b trial in patients with peripheral T-cell lymphoma. 

See here for more details: https://lnkd.in/efGecSJt

Today we announced a new pre-print published in bioRxiv that highlights the potential of ITK inhibition to treat a wide range of inflammatory and immune diseases. This includes data demonstrating that soquelitinib, our selective ITK inhibitor, was active in six inflammatory/immune disease models and has potential in a range of additional Th2- and Th17-mediated diseases. #immunology

To learn more about the preclinical data, read our press release: https://lnkd.in/e6cp9WMW

Join us at 1:30pm PT on Tuesday, November 7 when we will provide a business update and report our third quarter 2023 financial results. 
 
To register for and access the webcast, visit: https://lnkd.in/gVHCEKV

On Friday, our co-founder, president and CEO Richard Miller participated in a panel presentation covering a brief history of major advances in targeted therapy for cancer at an event hosted by the YPO SF. Dr. Miller shared his experience with the development of BTK inhibition with ibrutinib. The full panel included an enlightening discussion on the development of several other major classes of medicine, including monoclonal antibodies and cancer immunotherapy.
 
To learn more about Corvus’ pipeline, including a similar opportunity to BTK inhibition with the development of our ITK inhibitor soquelitinib, visit our website: https://lnkd.in/g5TdaKPh
 
#Cancer

We’re thrilled to confirm our plans to initiate Phase 3 trial to evaluate the efficacy and safety of soquelitinib in patients peripheral T cell lymphoma. Soquelitinib’s proposed mechanism of action, based on selective ITK inhibition, represents a platform opportunity with the potential to address a wide range of indications including hematologic cancers, solid tumors and autoimmune/allergic diseases.
 
Read our release to learn more what this means for the company and for information about our conference call: https://lnkd.in/g_gdquCi
 
#Lymphoma

Today we announced our second quarter 2023 financial results and provided a business update. We’re very pleased to be sharing updates on soquelitinib, our investigational selective ITK inhibitor, which we believe may offer a new approach to cancer immunotherapy based on its unique mechanism of action, as well as updates on our partner led programs.
 
To learn more, read our release: https://lnkd.in/gjrWjFe7

Join us at 1:30pm PT on Tuesday, August 8 when we will provide a business update and report our second quarter 2023 financial results. 
 
To register for and access the webcast, visit: https://lnkd.in/gVHCEKV

We’re proud to share meaningful pre-print data published in bioRxiv today which support our understanding that selective inhibition of ITK with soquelitinib (CPI-818) could potentially enhance anti-tumor immune response to hematologic and solid tumors and provide a novel approach to cancer immunotherapy. #Cancer #Immunology 
 
To learn more about the preclinical data, read our release: https://lnkd.in/gN4aas3D

Today we presented new preclinical data for ciforadenant highlighting its mechanism of action and synergy with immune checkpoint inhibitors via combination with anti-CTLA-4 and anti-PD-1 therapies at the Japanese Cancer Association and American Association for Cancer Research (#JCA-AACR) Precision Cancer Medicine International Conference in Kyoto, Japan. We’re pleased that the data further supports the rationale for the synergistic combination of ciforadenant with checkpoint inhibitors to leverage multiple components of the immune response to cancer. 
 
To learn more about the data, visit: https://lnkd.in/gPTdpDvU

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-31.34M -	-36.38M 16.08%	-55.66M 53.03%	-46.94M 15.67%	-46.67M 0.57%	-6.00M 87.16%	-43.24M 621.28%	-41.31M 4.47%	-27.03M 34.57%
depreciation and amortization	148K -	594K 301.35%	842K 41.75%	847K 0.59%	743K 12.28%	632K 14.94%	460K 27.22%	367K 20.22%	151K 58.86%
deferred income tax	-41K -	-3.83M 9,236.59%							-111K -
stock based compensation	428K -	3.83M 794.39%	6.23M 62.72%	7.13M 14.54%	7.35M 2.99%	5.75M 21.79%	4.23M 26.36%	2.69M 36.39%	2.15M 20.25%
change in working capital	1.83M -	3.45M 88.21%	2.58M 25.32%	-1.42M 155.26%	1.90M 233.80%	1.91M 0.26%	-3.24M 269.51%	1.41M 143.63%	111K 92.14%
accounts receivables							-507K -	-81K 84.02%	562K 793.83%
inventory
accounts payables	1.24M -	518K 58.23%	1.55M 200%	-1.46M 193.69%	450K 130.91%	1.02M 126.44%	-1.90M 286.65%	411K 121.61%	-451K 209.73%
other working capital	592K -	2.93M 394.93%	1.02M 65.15%	33K 96.77%	1.45M 4,306.06%	890K 38.79%	-827K 192.92%	1.08M 230.83%	-111K 110.26%
other non cash items	17.64M -	4.48M 74.63%	-195K 104.36%	-608K 211.79%	-644K 5.92%	-37.07M 5,656.37%	5.07M 113.68%	9.81M 93.55%	685K 93.02%
net cash provided by operating activities	-11.33M -	-27.86M 145.91%	-46.21M 65.89%	-40.99M 11.30%	-37.32M 8.95%	-34.78M 6.81%	-36.72M 5.57%	-27.02M 26.40%	-23.93M 11.43%
investments in property plant and equipment	-1.75M -	-2.20M 25.87%	-266K 87.90%	-355K 33.46%	-25K 92.96%	-76K 204%	-5K 93.42%	-269K 5,280%	-34K 87.36%
acquisitions net					-3.28K -	-44.84K 1,267.23%	-21.57K 51.91%	22K 202.02%
purchases of investments	-104.39M -	-258.28M 147.43%	-88.31M 65.81%	-161.86M 83.29%	-138.59M 14.38%	-42.54M 69.30%	-9.36M 78.00%	-66.19M 607.40%	-47.05M 28.92%
sales maturities of investments	14.10M -	217.92M 1,445.56%	173.40M 20.43%	132.02M 23.86%	141.87M 7.45%	87.39M 38.40%	30.92M 64.61%	43.16M 39.58%	62.62M 45.09%
other investing activites					3.28K -	44.84K 1,267.23%	21.57K 51.91%
net cash used for investing activites	-92.03M -	-42.56M 53.76%	84.83M 299.33%	-30.19M 135.59%	3.25M 110.78%	44.77M 1,275.39%	21.56M 51.84%	-23.28M 207.96%	15.54M 166.77%
debt repayment
common stock issued		71.35M -	711K 99.00%	64.88M 9,024.75%	24K 99.96%	1.22M 4,991.67%	60.94M 4,887.15%		7.84M -
common stock repurchased
dividends paid
other financing activites	94.95M -	4K 100.00%	731K 18,175%	393K 46.24%	24 99.99%	88K 366,566.67%	1.22M 1,280.68%		12K -
net cash used provided by financing activities	94.95M -	71.36M 24.85%	1.44M 97.98%	65.27M 4,426.35%	24K 99.96%	1.31M 5,358.33%	62.16M 4,644.89%		7.86M -
effect of forex changes on cash
net change in cash	-8.41M -	945K 111.23%	40.06M 4,138.73%	-5.91M 114.75%	-34.04M 476.01%	11.30M 133.20%	47.00M 315.92%	-50.30M 207.01%	-539K 98.93%
cash at beginning of period	12.52M -	4.11M 67.20%	5.05M 23.02%	45.11M 793.19%	39.20M 13.10%	5.15M 86.85%	16.45M 219.27%	63.46M 285.65%	13.16M 79.26%
cash at end of period	4.11M -	5.05M 23.02%	45.11M 793.19%	39.20M 13.10%	5.15M 86.85%	16.45M 219.27%	63.46M 285.65%	13.16M 79.26%	12.62M 4.10%
operating cash flow	-11.33M -	-27.86M 145.91%	-46.21M 65.89%	-40.99M 11.30%	-37.32M 8.95%	-34.78M 6.81%	-36.72M 5.57%	-27.02M 26.40%	-23.93M 11.43%
capital expenditure	-1.75M -	-2.20M 25.87%	-266K 87.90%	-355K 33.46%	-25K 92.96%	-76K 204%	-5K 93.42%	-269K 5,280%	-34K 87.36%
free cash flow	-13.07M -	-30.06M 129.87%	-46.48M 54.64%	-41.34M 11.05%	-37.35M 9.67%	-34.85M 6.67%	-36.72M 5.35%	-27.29M 25.68%	-23.97M 12.18%

NASDAQ:CRVS

Corvus Pharmaceuticals

Last Close

8.80

08/11 21:00

Market Cap

118.85M

Beta: 1.16

Volume Today

750.77K

Avg: 241.27K

PE Ratio

−2.66

PFCF: −3.80

Preview